Abstract

Objective: Resistance to immune checkpoint inhibitors (ICIs) has been a massive obstacle to ICI treatment in metastatic urothelial carcinoma (MUC). Recently, increasing evidence indicates the clinical importance of the association between hypoxia and immune status in tumor patients. Therefore, it is necessary to investigate the relationship between hypoxia and prognosis in metastatic urothelial carcinoma. Methods: Transcriptomic and clinical data from 348 MUC patients who underwent ICI treatment from a large phase 2 trial (IMvigor210) were investigated in this study. The cohort was randomly divided into two datasets, a training set (n = 213) and a testing set (n = 135). Data of hypoxia-related genes were downloaded from the molecular signatures database (MSigDB), and screened by univariate and multivariate Cox regression analysis to construct a prognosis-predictive model. The robustness of the model was evaluated in two melanoma cohorts. Furthermore, an external validation cohort, the bladder cancer cohort, from the Cancer Genome Atlas (TCGA) database, was t used to explore the mechanism of gene mutation, immune cell infiltration, signaling pathway enrichment, and drug sensitivity. Results: We categorized patients as the high- or low- risk group using a four-gene hypoxia risk model which we constructed. It was found that patients with high-risk scores had significantly worse overall survival (OS) compared with those with low-risk scores. The prognostic model covers 0.71 of the area under the ROC curve in the training set and 0.59 in the testing set, which is better than the survival prediction of MUC patients using the clinical characteristics. Mutation analysis results showed that deletion mutations in RB1, TP53, TSC1 and KDM6A were correlated with hypoxic status. Immune cell infiltration analysis illustrated that the infiltration T cells, B cells, Treg cells, and macrophages was correlated with hypoxia. Functional enrichment analysis revealed that a hypoxic microenvironment activated inflammatory pathways, glucose metabolism pathways, and immune-related pathways. Conclusion: In this investigation, a four-gene hypoxia risk model was developed to evaluate the degree of hypoxia and prognosis of ICI treatment, which showed a promising clinical prediction value in MUC. Furthermore, the hypoxia risk model revealed a close relationship between hypoxia and the tumor immune microenvironment.

Highlights

  • Metastatic urothelial carcinoma (MUC) is a common malignancy which occurs in the urothelial organs of the urinary system (Humphrey et al, 2016; Moch et al, 2016)

  • In this investigation, a four-gene hypoxia risk model was developed to evaluate the degree of hypoxia and prognosis of immune checkpoint inhibitors (ICIs) treatment, which showed a promising

  • The hypoxia risk model revealed a close relationship between hypoxia and the tumor immune microenvironment

Read more

Summary

Introduction

Metastatic urothelial carcinoma (MUC) is a common malignancy which occurs in the urothelial organs of the urinary system (Humphrey et al, 2016; Moch et al, 2016). Platinum-based chemotherapy is the first-line treatment for patients with metastatic urothelial carcinoma (Flaig et al, 2020; Witjes et al, 2021). According to the 2020 guidelines of the European Association of Urology (EAU), pembrolizumab and atezolizumab have become the first-line treatment option for locally advanced or metastatic urothelial carcinoma after failure of platinum chemotherapy (Witjes et al, 2021). In a phase III clinical trial involving 542 patients with advanced MUC after platinum chemotherapy, KEYNOTE-045 showed that the median overall survival (mOS) of the pembrolizumab group was longer than that of the second-line chemotherapy group by 3 months (10.3 vs 7.4 months; p 0.002) (Bellmunt et al, 2017). Exploring the mechanism of immunosuppressant in patients with metastatic urothelial carcinoma and seeking accurate predictive biomarkers is warranted

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.